Fig. 6.

A PP2A inhibitor suppresses EAE development. (A) PP2A WT and cKO mice were immunized with MOG_(35-55) peptide. PP2A inhibitor CAN (0.6 μg/g) was administered i.p. daily from day 10 to day 12 and then was given once every 2 d. Mean clinical scores for EAE from each group. (B) Representative histology of the spinal cord (H&E at Left and LFB at Right) of mice after EAE induction (day 19). Arrowheads indicate inflammatory infiltration (Left) and demyelination (Right). (Scale bars: 100 μm.) (C) Quantification of total mononuclear cells, CD4⁺ T cells, CD8⁺ T cells, and myeloid cells that infiltrated into the CNS of WT mice at peak of the disease. (D) Ratio of CD4⁺ and CD8⁺ T cells (gated at CD45^hi CD11b⁻) in the CNS of WT groups. (E and F) Ratio (E) and number (F) of IL17A⁺ or Foxp3⁺ or IFNγ⁺ CD4⁺ cells in the CNS of the WT groups at disease peak. (G) Quantification of total mononuclear cells, CD4⁺ T cells, CD8⁺ T cells, and myeloid cells that infiltrated into the CNS of the cKO groups. (H) Ratio of CD4⁺ and CD8⁺ T cells (gated at CD45^hi CD11b⁻) that infiltrated into the CNS of the cKO groups. Each symbol represents an individual mouse (n = 5–7 per genotype); error bars show mean ± SEM. Data are representative of two independent experiments with similar results.